May 14, 2020 -- High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible manufacturing facilities for vaccines.
Rapid deployment of prefabricated plants will enable rapid mass production and shortened time-to-market for vaccines against SARS-CoV-2, according to the companies. The capital and operational expenditures will be dramatically reduced with the prefabricated solution. The concept is meant to be scalable for rapid capacity ramp-up and accelerated market entry to assist with providing vaccines for global immunization.
Through the partnership, Exyte's ExyCellR modular technology will be combined with Univercells' NevoLine biomanufacturing platform with a scale-X fixed-bed bioreactor. The modules can be adapted to any process layout for the production of vector-based and live attenuated vaccines.